Medytox establishes a US corporation, headed by Mr. Albright, who contributed to the global expansion of Botox - South Korean news

Pharmaceutical company Medytox recently announced the establishment of a US subsidiary, Luvantas.
Luvantas, which is 100% owned by Medytox, is a US company.
Located in California. This company is in charge of promotional activities and marketing in the United States and Canada for MT10109, a non-animal liquid botulinum toxin developed in-house. After that, Hyalu
The company will also carry out activities to sell products such as the rononic acid filler "Neuramis" and the derma cosmetics "Neuradam" in developed countries.
The CEO of Luvantas is the Irish Pharmaceutical Association
Mr. Thomas Albright from Allergan, Inc. will be appointed. Mr. Albright was a driving force behind the expansion of sales of Botox, which is used for cosmetic purposes, in the world. botox markete
In addition to holding various leadership positions, he has also been involved in research and development of treatments for new indications and next-generation biologics.
Prior to this, on December 27, 2023, Medytox submitted to the U.S. Food and Drug Administration (FDA) “MT10
109" Biologics License Application (BLA) was submitted. "MT10109" does not use any animal-derived ingredients in the entire manufacturing process, such as culturing bacteria and manufacturing the stock solution, and it also contains human serum.
Because it does not contain rubumin (HAS) as an additive, it eliminates the possibility of infection with animal-derived viruses.